Verdemed

Verdemed’s mission is to offer the best of approved existing and prospective cannabinoid products to all Latin Americans, in all countries and in all jurisdictions legally authorized to sell medical cannabis.

The company’s focus is on product formulations of cannabinoid pharmaceuticals currently available in Canada, Europe, and the USA. Verdemed aims to meet Latin America’s medical needs with similar products and medical cannabis treatments approved by Health Canada, EMA (European Medicines Agency), and the USA FDA (Food and Drug Administration).

Verdemed is uniquely positioned to tackle the high regulatory hurdles in Latin America with Canadian-derived pharmaceutical products.

Over the past 20 years, Canada has built a robust regulatory framework to protect patients’ safety and to secure reliable treatments with medical cannabis products. Today most Latin American regulatory agencies have in place a regulatory regime similar to Canadian legislation around medical cannabis.

What We Do

Verdemed is a Canadian pharmaceutical cannabis company whose goal is to improve the health of millions of patients in Latin America.

With HQ and R&D based in Toronto, Canada, Verdemed’s multi-level and multi-market approach aims to bridge the gap between the European and North American cannabis pharmaceutical landscape and Latin American unmet clinical needs.

The company’s international footprint provides strategic access to market innovations, as well as well-known proven cannabis therapies. Verdemed operates to introduce to Latin America an ample range of cannabinoid-based medications in the next few years, fully approved by the principal regulatory agencies in the region – such as ANMAT, ANVISA, COFEPRIS, DIGEMID, INVIMA and ISP.

Latin America Partner of Choice for
Global Cannabis Pharmaceutical Companies

Verdemed aspires to become the platform of choice for global innovators entering the Latin American market with new medical cannabis products. The company is building strategic alliances and partnerships with global cannabis pharmaceutical companies to achieve this goal.

Verdemed will leverage its Canadian base and international presence to bring to Latin America pure pharmaceutical cannabinoid-based products that are currently in clinical trials around the world.

Verdemed also plans to conduct clinical trials in the larger Latin American countries with its partners involving proprietary formulations. The company will put innovative new products through the traditional pharmaceutical drug development approval process.

Verdemed will ensure that it offers only proven safe pharmaceutical products to doctors and patients in the region.

Benzinga Capital Cannabis Conference April 2019

The Benzinga Cannabis Capital Conference is the premier gathering of cannabis entrepreneurs and investors in North America, connecting entrepreneurs hoping to build billion-dollar cannabis enterprises with investors whose capital can help make that happen.